EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes

Lukas Galli, Johannes Bernhard, Lore Schrutka, Patrick Haider, Klaus Distelmaier, Christian Hengstenberg, Konstantin A Krychtiuk, Walter S Speidl

Clinical Research in Cardiology · 2026

DOI: 10.1007/s00392-025-02716-2 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Clinical Research in Cardiology, 2026. Verfasst von Lukas Galli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Practice Guidelines as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The European Society of Cardiology regularly updates its clinical practice guidelines. However, it is not well established whether guideline changes have significant effects on actual clinical practice. Therefore, we retrospectively analyzed lipid-lowering therapy at discharge after acute coronary syndrome (ACS) in a 1-year period before and a 1-year period after publication of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, respectively. Methods and results In total, we included 691 patients who were discharged alive after AMI. A total of 354 patients were treated in the period before, and 337 after the guideline change. After the guideline change, the proportion of patients discharged on high-dose statin was higher (89.3% vs 80.5%; p = 0.001) and ezetimibe was prescribed more often (31.2% vs 5.9%; p < 0.00001) resulting in more patients being discharged on high-intensity treatment (92.9% vs. 81.6%; p < 0.0001). Median on-treatment LDL-cholesterol was significantly higher in the period before (65 [IQR 47 to 90] mg/dL) than after the publication of the 2019 guidelines (48 [IQR 35 to 69] mg/dL; p < 0.0001). The LDL-C goal of < 55 mg/dL would have been reached by 37.5% patients in the earlier period and was reached by 62.9% in the later period ( p < 0.0001).

Conclusions

The update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias was associated with a significant improvement in the prescription of high-dose statin and ezetimibe in patients after ACS. The change of the guidelines rapidly translated into clinical practice resulting in improved risk factor control in patients at very high risk. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePractice Guidelines as TopicHydroxymethylglutaryl-CoA Reductase InhibitorsDyslipidemiasHumansMaleRetrospective StudiesFemaleAgedMiddle AgedEzetimibeCholesterol, LDLTreatment OutcomeAnticholesteremic Agents

Stichwörter der Autor:innen

Acute myocardial infarctionEvidence-based medicineGuidelinesImplementationLipid therapy

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsEzetimibeCholesterol, LDLAnticholesteremic Agents

Autor:innen und Institutionen

  • Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
  • Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
  • Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. Konstantin.krychtiuk@meduniwien.ac.at.

Förderung

  • Medical University of Vienna

Zitieren

APA

Galli, L., Bernhard, J., Schrutka, L., Haider, P., Distelmaier, K., Hengstenberg, C., Krychtiuk, K. A., & Speidl, W. S. (2026). Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-025-02716-2

Vancouver

Galli L, Bernhard J, Schrutka L, Haider P, Distelmaier K, Hengstenberg C, et al. Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-025-02716-2

BibTeX
@article{Galli2026,
  author = {Galli, Lukas and Bernhard, Johannes and Schrutka, Lore and Haider, Patrick and Distelmaier, Klaus and Hengstenberg, Christian and Krychtiuk, Konstantin A and Speidl, Walter S},
  title = {Effects of the 2019 guideline update on lipid-lowering therapy in patients with acute coronary syndromes},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-025-02716-2}
}
Kostenlos starten →